About PTC Therapeutics (NASDAQ:PTCT)
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy. It is developing Translarna, which is in Phase II clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 for the treatment of patients with spinal muscular atrophy, as well as PTC596, an orally bioavailable and potent small molecule that has completed Phase I study, which targets solid tumor cell populations by reducing the activity and amount of BMI1. The company has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTCT
CUSIPN/A
Phone908-222-7000
Debt
Debt-to-Equity Ratio0.93%
Current Ratio3.04%
Quick Ratio2.90%
Price-To-Earnings
Trailing P/E Ratio-14.27
Forward P/E Ratio-17.89
P/E GrowthN/A
Sales & Book Value
Annual Sales$194.39 million
Price / Sales6.53
Cash FlowN/A
Price / CashN/A
Book Value$3.77 per share
Price / Book7.36
Profitability
EPS (Most Recent Fiscal Year)($2.02)
Net Income$-79,000,000.00
Net Margins-40.64%
Return on Equity-50.75%
Return on Assets-20.90%
Miscellaneous
Employees373
Outstanding Shares45,800,000
PTC Therapeutics (NASDAQ:PTCT) Frequently Asked Questions
What is PTC Therapeutics' stock symbol?
PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT."
How were PTC Therapeutics' earnings last quarter?
PTC Therapeutics (NASDAQ:PTCT) released its quarterly earnings results on Tuesday, March, 6th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.17. The biopharmaceutical company had revenue of $78 million for the quarter, compared to analysts' expectations of $78.59 million. PTC Therapeutics had a negative net margin of 40.64% and a negative return on equity of 50.75%. The business's quarterly revenue was up 209.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.78) earnings per share. View PTC Therapeutics' Earnings History.
When is PTC Therapeutics' next earnings date?
What price target have analysts set for PTCT?
8 equities research analysts have issued 12-month price targets for PTC Therapeutics' shares. Their forecasts range from $15.00 to $35.00. On average, they expect PTC Therapeutics' stock price to reach $22.6667 in the next year. View Analyst Ratings for PTC Therapeutics.
What are Wall Street analysts saying about PTC Therapeutics stock?
Here are some recent quotes from research analysts about PTC Therapeutics stock:
- 1. According to Zacks Investment Research, "PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States. " (3/10/2018)
- 2. Cowen Inc analysts commented, "Yesterday Clearside announced the completion of enrollment in the TYBEE study in." (10/25/2017)
Are investors shorting PTC Therapeutics?
PTC Therapeutics saw a decrease in short interest during the month of April. As of April 13th, there was short interest totalling 4,260,918 shares, a decrease of 22.8% from the March 30th total of 5,521,035 shares. Based on an average daily trading volume, of 873,026 shares, the short-interest ratio is presently 4.9 days. Approximately 10.8% of the shares of the company are sold short.
Who are some of PTC Therapeutics' key competitors?
Some companies that are related to PTC Therapeutics include United Therapeutics (UTHR), Galápagos (GLPG), Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Tesaro (TSRO), Array BioPharma (ARRY), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE) and Amicus Therapeutics (FOLD).
Who are PTC Therapeutics' key executives?
PTC Therapeutics' management team includes the folowing people:
- Dr. Stuart W Peltz, Co-Founder, CEO & Exec. Director (Age 58)
- Dr. Allan Steven Jacobson, Co-Founder, Chairman of Scientific Advisory Board & Director (Age 72)
- Dr. Neil Almstead Ph.D., Exec. VP of Research, Pharmaceutical Operations & Technology (Age 51)
- Mr. Mark Elliott Boulding, Chief Legal Officer, EVP & Sec. (Age 57)
- Ms. Christine Utter, Principal Financial & Accounting Officer and Treasurer
Has PTC Therapeutics been receiving favorable news coverage?
News coverage about PTCT stock has been trending positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. PTC Therapeutics earned a news sentiment score of 0.28 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 47.94 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of PTC Therapeutics?
Shares of PTCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PTC Therapeutics' stock price today?
One share of PTCT stock can currently be purchased for approximately $27.73.
How big of a company is PTC Therapeutics?
PTC Therapeutics has a market capitalization of $1.21 billion and generates $194.39 million in revenue each year. The biopharmaceutical company earns $-79,000,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. PTC Therapeutics employs 373 workers across the globe.
How can I contact PTC Therapeutics?
PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company can be reached via phone at 908-222-7000 or via email at [email protected].
MarketBeat Community Rating for PTC Therapeutics (PTCT)
MarketBeat's community ratings are surveys of what our community members think about PTC Therapeutics and other stocks. Vote "Outperform" if you believe PTCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
PTC Therapeutics (NASDAQ:PTCT) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for PTC Therapeutics in the last 12 months. Their average twelve-month price target is $22.6667, suggesting that the stock has a possible downside of 18.26%. The high price target for PTCT is $35.00 and the low price target for PTCT is $15.00. There are currently 2 sell ratings, 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.13 | 2.13 | 2.00 |
| Ratings Breakdown: | 2 Sell Rating(s)
4 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 2 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $22.6667 | $22.3333 | $19.1667 | $16.75 |
| Price Target Upside: | 18.26% downside | 22.86% downside | 14.81% downside | 3.18% downside |
PTC Therapeutics (NASDAQ:PTCT) Consensus Price Target History
PTC Therapeutics (NASDAQ:PTCT) Analyst Ratings History
Show:
(Data available from 4/26/2016 forward)
PTC Therapeutics (NASDAQ:PTCT) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
PTC Therapeutics (NASDAQ PTCT) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 8.10%
Institutional Ownership Percentage: 83.26%
PTC Therapeutics (NASDAQ PTCT) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/5/2018 | Stuart Walter Peltz | CEO | Sell | 2,230 | $18.03 | $40,206.90 | 26,646 |  |
| 1/4/2018 | Christine Marie Utter | Insider | Sell | 412 | $17.67 | $7,280.04 | | |
| 1/4/2018 | Neil Gregory Almstead | EVP | Sell | 77 | $17.67 | $1,360.59 | | |
| 5/23/2017 | Dawn Svoronos | Director | Buy | 25,000 | $13.49 | $337,250.00 | 25,000 | |
| 1/5/2017 | Neil Gregory Almstead | EVP | Sell | 78 | $11.82 | $921.96 | | |
| 3/3/2016 | Mark Rothera | Insider | Buy | 2,000 | $6.23 | $12,460.00 | 5,125 | |
| 7/6/2015 | David P Southwell | Director | Sell | 23,604 | $47.52 | $1,121,662.08 | | |
| 6/18/2015 | Allan Steven Jacobson | Director | Sell | 5,000 | $50.13 | $250,650.00 | | |
| 6/9/2015 | Stuart Walter Peltz | CEO | Sell | 100,000 | $54.49 | $5,449,000.00 | | |
| 6/8/2015 | Mark Elliott Boulding | VP | Sell | 56,849 | $55.04 | $3,128,968.96 | | |
| 6/8/2015 | Richard Aldrich | Director | Sell | 7,000 | $55.66 | $389,620.00 | | |
| 6/8/2015 | Stuart Walter Peltz | CEO | Sell | 73,700 | $54.91 | $4,046,867.00 | | |
| 5/22/2015 | Shane William Charles Kovacs | CFO | Sell | 82,491 | $55.41 | $4,570,826.31 | | |
| 4/15/2015 | Neil Gregory Almstead | EVP | Sell | 9,511 | $68.65 | $652,930.15 | | |
| 3/23/2015 | David P Southwell | Director | Sell | 2,317 | $69.04 | $159,965.68 | | |
| 3/23/2015 | Stuart Walter Peltz | CEO | Sell | 47,200 | $69.14 | $3,263,408.00 | | |
| 3/20/2015 | Mark Elliott Boulding | VP | Sell | 21,142 | $68.12 | $1,440,193.04 | | |
| 3/18/2015 | Allan Steven Jacobson | Director | Sell | 16,616 | $76.00 | $1,262,816.00 | | |
| 3/17/2015 | Mark Rothera | Insider | Sell | 10,700 | $76.64 | $820,048.00 | | |
| 3/16/2015 | Michael L Kranda | Director | Sell | 2,500 | $72.81 | $182,025.00 | | |
| 3/13/2015 | Robert J Spiegel | Insider | Sell | 1,030 | $75.10 | $77,353.00 | | |
| 3/10/2015 | Neil Gregory Almstead | EVP | Sell | 79 | $70.71 | $5,586.09 | | |
| 3/9/2015 | Stuart Walter Peltz | CEO | Sell | 47,201 | $70.74 | $3,338,998.74 | | |
| 2/25/2015 | Mark Rothera | Insider | Sell | 35,000 | $68.01 | $2,380,350.00 | | |
| 2/24/2015 | Mark Rothera | Insider | Sell | 1,000 | $67.70 | $67,700.00 | | |
| 2/23/2015 | Mark Rothera | Insider | Sell | 23,000 | $65.40 | $1,504,200.00 | | |
| 1/21/2015 | Neil Gregory Almstead | EVP | Sell | 26,096 | $60.26 | $1,572,544.96 | | |
| 1/20/2015 | Mark Rothera | Insider | Sell | 3,000 | $60.02 | $180,060.00 | | |
| 1/16/2015 | Mark Rothera | Insider | Sell | 2,300 | $58.67 | $134,941.00 | | |
| 1/15/2015 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,149 | $57.19 | $122,901.31 | | |
| 1/14/2015 | Mark Rothera | Insider | Sell | 9,700 | $58.04 | $562,988.00 | | |
| 12/15/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,173 | $55.24 | $120,036.52 | | |
| 11/17/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 2,173 | $39.78 | $86,441.94 | | |
| 10/15/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 45,661 | $36.15 | $1,650,645.15 | | |
| 10/10/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 43,489 | $36.18 | $1,573,432.02 | | |
| 10/1/2014 | Stuart Walter Peltz | CEO | Sell | 41,501 | $42.65 | $1,770,017.65 | | |
| 9/26/2014 | Mark Rothera | Insider | Sell | 16,000 | $44.63 | $714,080.00 | | |
| 9/18/2014 | Allan Steven Jacobson | Director | Sell | 2,000 | $40.16 | $80,320.00 | | |
| 9/15/2014 | Mark Rothera | Insider | Sell | 8,000 | $36.24 | $289,920.00 | | |
| 5/22/2014 | Shane William Charles Kovacs | CFO | Sell | 1,650 | $14.74 | $24,321.00 | 12,350 | |
| 3/24/2014 | Stuart Walter Peltz | CEO | Sell | 25,487 | $29.86 | $761,041.82 | 135,902 | |
| 3/21/2014 | Claudia De Oliveira Ri Hirawat | President | Sell | 15,320 | $29.61 | $453,625.20 | 34,737 | |
| 3/21/2014 | David Southwell | Director | Sell | 2,317 | $30.93 | $71,664.81 | 10,921 | |
| 3/20/2014 | Mark Elliott Boulding | VP | Sell | 10,049 | $30.96 | $311,117.04 | 32,235 | |
| 3/19/2014 | Neil Gregory Almstead | VP | Sell | 10,859 | $31.91 | $346,510.69 | 29,881 | |
| 3/18/2014 | Allan Steven Jacobson | Director | Sell | 7,616 | $31.18 | $237,466.88 | 30,464 | |
| 3/14/2014 | Michael Kranda | Director | Sell | 1,186 | $31.02 | $36,789.72 | 4,742 | |
| 3/13/2014 | Robert Spiegel | Insider | Sell | 1,186 | $31.75 | $37,655.50 | 4,269 | |
| 3/7/2014 | Stuart Walter Peltz | CEO | Sell | 27,414 | $29.91 | $819,952.74 | 161,389 | |
| 12/17/2013 | Hbm Healthcare Investments (Ca | major shareholder | Sell | 66,667 | $19.08 | $1,272,006.36 | 2,441,504 | |
| 6/25/2013 | Adam Koppel | Director | Buy | 1,250,000 | $15.00 | $18,750,000.00 | | |
| 6/25/2013 | Hbm Healthcare Investments (Ca | Major Shareholder | Buy | 666,676 | $15.00 | $10,000,140.00 | | |
| 6/25/2013 | Mark Rothera | Insider | Buy | 25,000 | $15.00 | $375,000.00 | | |
(Data available from 1/1/2013 forward)
PTC Therapeutics (NASDAQ PTCT) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | PTC Therapeutics (PTCT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 19 at 3:34 PM |
| PTC Therapeutics (PTCT) Forecasted to Post Q1 2018 Earnings of ($0.61) Per Share
www.americanbankingnews.com - April 18 at 7:42 AM |
| PTC Therapeutics (PTCT) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - April 15 at 7:31 PM |
 | Free Research Reports on These Biotech Stocks -- Prothena, PTC Therapeutics, Pulmatrix, and Puma Biotech
www.prnewswire.com - April 13 at 7:22 AM |
 | PTC Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
finance.yahoo.com - April 12 at 5:19 PM |
| PTC Therapeutics (PTCT) Downgraded by JPMorgan Chase
www.americanbankingnews.com - April 7 at 8:50 PM |
| PTC Therapeutics (PTCT) Downgraded by Bank of America
www.americanbankingnews.com - April 4 at 8:34 PM |
| PTC Therapeutics and CHDI Foundation Announce a Collaboration on a Small-Molecule Therapeutic for Huntington's Disease
finance.yahoo.com - April 4 at 8:39 AM |
| PTC Therapeutics (PTCT) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 3 at 9:18 PM |
| Barclays Lowers PTC Therapeutics (PTCT) to Underweight
www.americanbankingnews.com - April 3 at 5:16 PM |
| PTC Therapeutics (PTCT) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - March 30 at 1:18 PM |
| PTC Therapeutics Sees Unusually High Options Volume (PTCT)
www.americanbankingnews.com - March 30 at 7:06 AM |
| PTC Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 27 at 5:01 PM |
| Credit Suisse Group Reiterates Buy Rating for PTC Therapeutics (PTCT)
www.americanbankingnews.com - March 26 at 4:18 PM |
| PTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 7:36 PM |
| FIREFISH Transitions into Pivotal Phase - PR Newswire - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:40 AM |
| FIREFISH Transitions into Pivotal Phase
finance.yahoo.com - March 15 at 8:34 AM |
| PTC Therapeutics (PTCT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - March 10 at 6:06 AM |
| Q1 2018 EPS Estimates for PTC Therapeutics, Inc. (PTCT) Lowered by William Blair
www.americanbankingnews.com - March 9 at 7:26 AM |
| PTC Therapeutics, Inc. Forecasted to Earn Q1 2019 Earnings of ($0.38) Per Share (PTCT)
www.americanbankingnews.com - March 8 at 11:50 AM |
| PTC Therapeutics (PTCT) Price Target Raised to $24.00
www.americanbankingnews.com - March 7 at 4:15 PM |
| PTC Therapeutics (PTCT) Receives Hold Rating from William Blair
www.americanbankingnews.com - March 7 at 12:45 PM |
 | PTC Therapeutics Q4 Earnings Preview - Benzinga
www.benzinga.com - March 7 at 8:41 AM |
| Investor Expectations to Drive Momentum within AVEO Pharmaceuticals, PTC Therapeutics, NGL Energy Partners LP, Bemis, CorMedix, and Patterson Companies — Discovering Underlying Factors of Influence
finance.yahoo.com - March 7 at 8:41 AM |
| PTC Therapeutics (PTCT) Issues Quarterly Earnings Results, Beats Expectations By $0.25 EPS
www.americanbankingnews.com - March 6 at 9:12 PM |
| PTC Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - March 6 at 5:27 PM |
| PTC Therapeutics Q4 Earnings Preview
finance.yahoo.com - March 6 at 5:27 PM |
| PTC Therapeutics posts 4Q profit
finance.yahoo.com - March 6 at 5:27 PM |
| PTC Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 6 at 5:27 PM |
| PTC Therapeutics, Inc. (PTCT) Holdings Raised by Sectoral Asset Management Inc
www.americanbankingnews.com - March 5 at 4:07 PM |
| Zuckerman Investment Group LLC Invests $1.23 Million in PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - March 5 at 2:25 PM |
| Bogle Investment Management L P DE Sells 396,777 Shares of PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - March 5 at 5:10 AM |
| Hudson Bay Capital Management LP Acquires Shares of 60,000 PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - March 3 at 12:51 PM |
| PTC Therapeutics (PTCT) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - February 27 at 4:29 AM |
| Spark Investment Management LLC Acquires 320,200 Shares of PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - February 25 at 2:31 PM |
| American Century Companies Inc. Lowers Position in PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - February 25 at 4:06 AM |
| PTC Therapeutics, Inc. (PTCT) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - February 24 at 7:38 PM |
| Pinnacle Associates Ltd. Lowers Holdings in PTC Therapeutics, Inc. (PTCT)
www.americanbankingnews.com - February 24 at 2:42 PM |
| PTC Therapeutics, Inc. (PTCT) Expected to Announce Quarterly Sales of $71.14 Million
www.americanbankingnews.com - February 24 at 3:06 AM |
| PTC Therapeutics Sees Unusually Large Options Volume (PTCT)
www.americanbankingnews.com - February 23 at 8:26 AM |
| PTC Therapeutics (PTCT) Price Target Raised to $35.00
www.americanbankingnews.com - February 21 at 12:42 PM |
| PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2017 Financial Results
finance.yahoo.com - February 21 at 8:39 AM |
| PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs
finance.yahoo.com - February 20 at 8:29 AM |
| PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy - PR Newswire (press release)
www.prnewswire.com - February 15 at 8:05 AM |
| PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy
finance.yahoo.com - February 13 at 9:49 AM |
| PTC Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
finance.yahoo.com - February 9 at 9:43 AM |
| $71.14 Million in Sales Expected for PTC Therapeutics, Inc. (PTCT) This Quarter
www.americanbankingnews.com - February 7 at 4:02 AM |
| Analysts Expect PTC Therapeutics, Inc. (PTCT) to Announce -$0.02 EPS
www.americanbankingnews.com - February 5 at 3:10 PM |
| PTC Therapeutics, Inc. (PTCT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 30 at 7:30 PM |
| PTC Therapeutics (PTCT) Research Coverage Started at Royal Bank of Canada
www.americanbankingnews.com - January 29 at 9:06 AM |
PTC Therapeutics (NASDAQ:PTCT) SEC Filings
This page is loading this company's SEC Filings. Please wait...
PTC Therapeutics (NASDAQ:PTCT) Income Statement, Balance Sheet and Cash Flow Statement
PTC Therapeutics (NASDAQ PTCT) Stock Chart for Thursday, April, 26, 2018
Loading chart…
